Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Secures $10M Loan

NEW YORK (GenomeWeb) – Human DNA identification firm IntegenX and Horizon Technology Finance said on Monday that IntegenX has secured a $10 million venture loan.

The loan will be used primarily for working capital. Horizon was the lead lender and committed $3.75 million. Square 1 Bank committed $2.5 million, and a third undisclosed lender committed $3.75 million.

In a statement IntegenX Chief Operating Officer David Smith said the loan provides the company greater financial flexibility and positions it to build off its momentum to increase sales of its RapidHit DNA analysis system, an automated platform that generates DNA profiles from reference samples.

Biometric solutions firm Morpho and IntegenX signed a deal earlier this year to market the RapidHit system to enforcement and government agencies in certain countries.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.